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Abstract
Capreomycin and the structurally similar compound viomycin are cyclic peptide antibiotics
which are particularly active against Mycobacterium tuberculosis, including multi-drug
resistant strains. Both antibiotics bind across the ribosomal interface involving 23S rRNA helix
69 (H69) and 16S rRNA helix 44 (h44). The binding site of tuberactinomycins in h44 partially
overlaps with that of aminoglycosides and they share with these drugs the side effect of
irreversible hearing loss. Here we studied the drug-target interaction on ribosomes modified
by site-directed mutagenesis. We identified rRNA residues in h44 as the main determinants of
phylogenetic selectivity, predict compensatory evolution to impact on future resistance
development and propose mechanisms involved in tuberactinomycin ototoxicity which may
enable the development of improved less toxic derivatives.
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Abstract 23 
Capreomycin and the structurally similar compound viomycin are cyclic peptide antibiotics 24 
which are particularly active against Mycobacterium tuberculosis, including multi-drug 25 
resistant strains. Both antibiotics bind across the ribosomal interface involving 23S rRNA 26 
helix 69 (H69) and 16S rRNA helix 44 (h44). The binding site of tuberactinomycins in h44 27 
partially overlaps with that of aminoglycosides and they share with these drugs the side effect 28 
of irreversible hearing loss. Here we studied the drug-target interaction on ribosomes 29 
modified by site-directed mutagenesis. We identified rRNA residues in h44 as the main 30 
determinants of phylogenetic selectivity, predict compensatory evolution to impact on future 31 
resistance development and propose mechanisms involved in tuberactinomycin ototoxicity 32 
which may enable the development of improved less toxic derivatives.  33 
Introduction 34 
Tuberculosis has been declared a global public health emergency by the World Health 35 
Organisation. Worldwide in 2000, there were about 9 million new cases and 2 million deaths 36 
due to tuberculosis (10). The emergence of multidrug-resistant (MDR) tuberculosis has 37 
further complicated treatment and control of the disease (1). Capreomycin and viomycin 38 
belong to the tuberactinomycins, an important class of antibiotics with activity against 39 
multidrug-resistant tuberculosis (12). 40 
Tuberactinomycins are cyclic peptide antibiotics (for chemical structures see Suppl. Fig. 1) 41 
which target bacterial protein synthesis by binding to the well-conserved intersubunit bridge 42 
B2a formed by interaction between helix H69 of the 23S rRNA and helix h44 of the 16S 43 
rRNA (34) (Fig. 1 A-C). Inhibition of translocation during peptide elongation is the main 44 
mechanism of drug action mediating the compound’s antibacterial activity (24, 26). 45 
Mutational alterations of nucleotides in 23S or 16S rRNA affect drug binding (8, 13, 18, 20, 46 
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37). In addition, the loss of 2’-O-methylation of C1920 (rRNA nucleotides are numbered 47 
according to Escherichia coli throughout the paper) in H69 and of C1409 in h44 by TlyA 48 
reduces susceptibility to capreomycin (17, 21). Interestingly, Thermus thermophilus TlyA 49 
modifies only C1920 in H69 of 23S rRNA, but not C1409 in h44 of 16S rRNA. Inactivation 50 
of tlyA in T. thermophilus does not affect its sensitivity to capreomycin (25), suggesting that 51 
modification of C1409 is the relevant determinant of increased drug susceptibility due to 2’-52 
O-methylation. 53 
Much of the unwanted side effects of ribosomal antibiotics reflect limitations in selectivity (2, 54 
3), as has been demonstrated for chloramphenicol and linezolid (23, 38). Together with the 55 
structurally unrelated class of aminoglycoside antibiotics, the tuberactinomycins share 56 
ototoxicity (irreversible loss of hearing) as a common and unique side effect (7, 35). 57 
Tuberactinomycins affect bacterial protein synthesis apparently by stabilizing peptidyl-tRNA 58 
in the pretranslocation complex preventing translocation of the ribosome along the mRNA 59 
(11, 19, 24, 26). The recent crystal structure of the 70S ribosome from T. thermophilus in 60 
complex with viomycin or capreomycin at 3.3 - 3.5 Angstrom resolution has delineated 61 
important details on drug binding and mechanisms of translocation inhibition (34) (Fig. 1 A-62 
C). Based on the structural information available we set out to characterize the drug-target 63 
interaction in molecular detail. Specifically, we investigated structure-function relationships 64 
by assessing the compounds’ determinants of specificity, selectivity and resistance 65 
development.  66 
Materials and Methods 67 
Bacterial strains and DNA techniques  68 
Mycobacterium smegmatis strains mc2 155 SmS ∆rrnB and mc2 155 SmS ∆rrnB ∆rrnA attB : 69 
rrnB were used for all experiments. Strategies used to generate the isogenic mutants under 70 
AAC00628-11 Version 2 
AAC00628-11 Version 2  4/23 
study have been described in detail elsewhere and included: (i) transformation with plasmids 71 
carrying the rRNA alteration of interest and subsequent integration into the chromosomal 72 
rrnA operon by means of homologous recombination (27, 28) and (ii) gene replacement by 73 
plasmid exchange (15). Successful gene replacement was controlled by sequence analysis. 74 
For a detailed list of plasmids and strains used see Supplementary Tables 1 and 2. 75 
Clinical strains of Mycobacterium tuberculosis were obtained from the Diagnostic 76 
Department, Institute of Medical Microbiology, University of Zurich. Drug resistant 77 
derivatives of Mycobacterium bovis BCG were generated by selective plating. 78 
Isolation and purification of ribosomes 79 
Ribosomes were purified from bacterial cell pellets by sucrose gradient (10-40%) 80 
centrifugation as described previously (6). Ribosome concentrations of 70S were determined 81 
by absorption measurements on the basis of 23 pmol ribosomes per A260 unit. Integrity and 82 
functional activity of purified 70S ribosomes was determined by analytical ultracentrifugation 83 
and by assessing their capacity to form initiation complexes (6).  84 
Cell-free luciferase translation assays  85 
Purified 70S hybrid ribosomes and in-vitro transcribed mRNA were used in translation 86 
reactions. Firefly luciferase mRNA was produced using T7 RNA polymerase in-vitro. A 87 
typical translation reaction contained 0.25 µM 70S ribosomes, 500 ng mRNA, 40% (vol/vol) 88 
of M. smegmatis S100 extract, 200 µM amino acid mixture, 0.3 µL 50 x protease inhibitor 89 
cocktail (Roche) and RNasin (40 units; Promega), 0.4 mg/ml of tRNAs, and 6 µL of 90 
commercial S30 Premix without Amino Acids (Promega). The total volume of reaction was 91 
15 µL. The reaction mixture was incubated at 37°C and stopped on ice. Finally, 100 µL of 92 
luciferase assay substrate (Promega) were added and the bioluminescence was measured in a 93 
luminometer (Bio-Tek Instruments; FLx800). 94 
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Misreading was assessed in a gain of function assay. We introduced Arg245 (CGC near-95 
cognate) into firefly luciferase to replace the functionally important amino acid His245 (CAC 96 
codon). As a negative control we introduced the Arg245 non-cognate AGA codon, as 97 
ribosomal misreading affects decoding of near-cognate codons but not that of non-cognate 98 
codons (30). Firefly (F-luc) and renilla luciferase (R-luc) mRNAs were produced using T7 99 
polymerase in-vitro on templates of modified plasmids pGL4.14 (F-luc) and pGL4.75 (R-luc) 100 
(both Promega). Mutant 245 F-luc and wt F-luc mRNA was used in in-vitro translation 101 
reactions along with R-luc mRNA serving as internal control. We quantified misreading by 102 
calculating mutant firefly/renilla luciferase as compared to wild-type firefly/renilla luciferase 103 
activity. A typical translation reaction contained 0.25 µM 70S ribosomes, 4 µg firefly (F-luc) 104 
mRNA, 0.4 µg renilla luciferase (R-luc) mRNA, 40% (vol/vol) of M. smegmatis S100 extract, 105 
200 µM amino acid mixture, 0.6 µL 50 x protease inhibitor cocktail (Roche) and RNasin (80 106 
units; Promega), 0.4 mg/ml of tRNAs, and 12 µL of commercial S30 Premix without Amino 107 
Acids (Promega). The total volume of reaction was 30 µL. The reaction mixture was 108 
incubated at 37°C and stopped on ice. Luciferase activity was measured using Dual-109 
Luciferase reporter system (Promega). After incubation, 100 µL of F-luc substrate were added 110 
and the firefly luciferase bioluminescence was measured. Finally, 100 µL of R-luc substrate 111 
were added and the renilla luciferase bioluminescence was measured (Bio-Tek Instruments; 112 
FLx800). 113 
Antibiotics 114 
Capreomycin was obtained from Sigma (Cat. No. C4142) and viomycin from Tocris 115 
Bioscience (Cat. No. 3787)  116 
Minimal inhibitory concentrations (MIC) and fitness assays  117 
AAC00628-11 Version 2 
AAC00628-11 Version 2  6/23 
Broth microdilution tests were performed in a microtitre plate format in triplicates for the 118 
mutants indicated as described previously (15). 119 
Drug susceptibility of M. tuberculosis and M. bovis BCG was assessed using the MGIT960 120 
instrumentation equipped with the TBeXiST software (Becton-Dickinson) as described (33). 121 
The cost of a resistance mutation was determined by direct competition against the isogenic 122 
drug-susceptible parental strain as described previously (14, 32).  123 
Figure preparation  124 
Figure 1 panels A, B, D and E were prepared using PyMol (DeLano WL 2002, The PyMol 125 
molecular graphics system, San Carlos Calif. DeLano Scientific) from the atomic coordinates 126 
in PDB accession numbers 3KNL, 3KNM (capreomycin) and 3KNH, 3KNI (viomycin) (37). 127 
Results 128 
Determinants of antibacterial activity and fitness of drug resistance mutations 129 
To study the relative contribution of individual drug-nucleotide contacts to antibacterial 130 
activity, we assessed minimal inhibitory concentrations (MIC) of recombinant 131 
Mycobacterium smegmatis constructed previously (32) with point mutations in the h44 drug 132 
binding pocket introduced by site-directed mutagenesis (Table 1). The point mutations sample 133 
viable mutational alterations of 16S rRNA key residues participating in drug binding, i.e. 134 
A1408G, C1409U/G, G1491A/C/U (see Fig. 1 F; note that A1408C/U and C1409A 135 
mutational alterations confer lethality). 1408A→G has limited effects, as it in part decreases 136 
susceptibility to capreomycin (4-8 fold increase in MIC compared to the wild-type) but not 137 
that to viomycin. In contrast, mutational alterations of base pair C1409-G1491 significantly 138 
affect drug susceptibility, in particular alterations which result in a purine-pyrimidine 139 
(G1491C/U) or in a pyrimidine-purine (C1409G) switch (relative resistance 100-200 fold).  140 
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Mutations C1409U and G1491U are associated with capreomycin resistance in 141 
Mycobacterium tuberculosis (13, 18, 20) and confer a significant fitness cost. More recently, 142 
it has been observed that a secondary site G1491A alteration restoring base-pair interaction 143 
between the 1409U mutant and residue 1491 evolves in M. tuberculosis to ameliorate the cost 144 
of the 1409U resistance mutation (32). We studied the three possible secondary-site mutations 145 
in M. smegmatis which would restore 1409-1491 base pairing for any of the resistance 146 
mutations affecting residue 1409 or 1491, i.e. interactions 1409G-1491C, 1409U-1491A, 147 
1409A-1491U (see Fig. 2). Restoration of 1409-1491 base pairing in part ameliorated fitness 148 
(32) but was still associated with a significant degree of tuberactinomycin resistance (see 149 
Table 1). Of note, the 1409A-1491U interaction retains a high level of drug resistance similar 150 
to that of the 1491U resistance alteration alone, yet the 1409A alteration restores the fitness of 151 
the 1491U resistance mutation (cost per generation, cpg 11.7% ± 5.9) to wild-type levels (cpg 152 
of 1409A - 1491U: 0.1% ± 2.9). 153 
Mechanisms involved in selectivity and toxicity  154 
The mechanism of action of capreomycin and viomycin involves both ribosomal subunits and 155 
thus is unique among the ribosome-targeting antibiotics. To study drug selectivity we used 156 
hybrid ribosomes (14, 15) with the bacterial h44 replaced by the corresponding cytosolic 157 
homolog, resulting in bacterial ribosomes with a humanized drug binding pocket (cyt 14 in 158 
Fig. 2). In comparison to native eukaryotic cytosolic ribosomes (rabbit reticulocytes) this 159 
should allow the relative contribution of H69 in 23S rRNA to drug selectivity to be 160 
determined. Ribosomal drug susceptibility (inhibition of protein synthesis) was assessed in 161 
cell-free luciferase translation assays. Compared to bacterial ribosomes rabbit reticulocytes 162 
demonstrated a 3 log10 difference in drug susceptibility. The IC50 inhibitory values of bacterial 163 
ribosomes with a humanized h44 drug binding pocket were in the same range as those of 164 
rabbit reticulocytes (Table 2). To define the relevant polymorphic residues relevant for 165 
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phylogenetic specificity more precisely, we further constructed ribosomes with the humanized 166 
part of h44 further shortened by mutagenesis to result in bacterial ribosomes with the human 167 
1408G and the human 1491A homolog (cyt 2). Drug susceptibility of cyt 2 ribosomes was 168 
comparable to that of cyt 14 ribosomes and rabbit ribosomes (Table 2). From these results we 169 
conclude that the phylogenetic variability within h44, more precisely 16S rRNA residues 170 
1408 and 1491, is sufficient to account for the drug’s ability to discriminate between bacterial 171 
and eukaryotic cytosolic ribosomes.  172 
Mitochondrial mistranslation has been identified as an important mechanism contributing to 173 
aminoglycoside ototoxicity (14, 16). In addition, aminoglycoside ototoxicity occurs in a 174 
genetically inherited form, with drug hypersusceptibility linked to alterations A1555G or 175 
C1494U in mitochondrial rRNA (29, 39). Both mutations locate to the mitoribosomes’ 176 
decoding A site and replace a C-A non Watson-Crick interaction with canonical C-G or U-A 177 
base pairing, respectively (see Fig. 2). Having provided evidence that the large ribosomal 178 
subunit contributes little to drug selectivity, we used the hybrid ribosome approach to study 179 
the activity of tuberactinomycins against the wild-type mitochondrial h44 drug-binding 180 
pocket versus the A1555G and C1494U mutants. In comparison to wild-type mitohybrid 181 
ribosomes the mutant hybrids were found to be significantly more susceptible to 182 
tuberactinomycins (Table 2, p < 0.0001 Student’s t-test). To study misreading we established 183 
a sensitive gain-of-function assay. We replaced the functionally important amino acid His245 184 
(CAC codon) in the active site of luciferase with the near-cognate CGC codon Arg245. 185 
Replacement of His by Arg245 completely eliminates enzymatic activity of the firefly 186 
protein, with activity restored by misreading. As a negative control we introduced the Arg245 187 
non-cognate AGA codon, as ribosomal misreading affects decoding of near-cognate codons 188 
but not that of non-cognate codons (30). In contrast to bacterial ribosomes (9, 19), the 189 
tuberactinomycin compounds readily induced misreading of the near-cognate CGC codon on 190 
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mitohybrid ribosomes (Fig. 3). This drug-mediated gain of enzymatic function upon 191 
mistranslation of the Arg245 mutant luciferase mRNA was further aggravated in the A1555G 192 
and C1494U mutants. 193 
Discussion 194 
Mutations in 16S rRNA positions 1408, 1409 and 1491 are associated with varying degrees of 195 
resistance to capreomycin and viomycin in M. tuberculosis, while simultaneously conferring 196 
in part cross-resistance to the aminoglycosides amikacin and kanamycin (13, 18, 20, 22, 36). 197 
Our results refine the role of individual 16S nucleotides in drug binding and resistance (for a 198 
comparison to clinical resistant isolates of M. tuberculosis complex and strains generated by 199 
selective plating see Suppl. Table 3). In addition, by modelling compensatory evolution in M. 200 
smegmatis we can tentatively predict resistance development in M. tuberculosis. Our results 201 
lead us to suggest that the more widespread use of capreomycin may lead to compensatory 202 
evolution, in particular by selection for the C1409A–G1491U mutant, allowing for resistance 203 
which comes at little cost and which will spread rapidly, as has been observed for 204 
streptomycin resistance in M. tuberculosis (4, 5, 31).  205 
Both capreomycin and viomycin bind to the 70S in a cleft formed between H69 of 23S rRNA 206 
and h44 of 16S rRNA (see Fig. 1). The macrocycle, capreomycidine ring and the 207 
ureidodehydroalanine form numerous hydrogen bonds to the ribose phosphate backbone of 208 
A1913, C1914 (both 23S rRNA) and A1493 (16S rRNA); side groups of the macrocycle also 209 
form contacts to G1491 or A1408 (both 16S rRNA). Despite the close contacts of the 210 
tuberactinomycin antibiotics to the phosphate backbone of 23S rRNA residues A1913 and 211 
C1914, the polymorphism within h44 of the 16S rRNA is sufficient to account for drug 212 
selectivity, leading us to suggest that H69 in the large ribosomal subunit apparently 213 
contributes little towards the drug’s ability to discriminate between bacterial and eukaryotic 214 
cytosolic ribosomes. This is consistent with the high degree of conservation of H69 with 215 
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A1913 and C1914 being identical between bacteria and eukaryotes. Compared to viomycin 216 
the 1408A→G mutation has a small but significant effect on capreomycin susceptibility 217 
(relative resistance 8-fold). This finding is explained by the crystal structure, which suggests 218 
two (albeit weak) H-bonds between A1408 and capreomycin, but no direct interaction of 219 
residue 1408 with viomycin (see Fig. 1 D-E). As a result of the A1408G substitution, the 220 
direct interaction of residue 1408 with capreomycin would be limited to a single H-bond. 221 
There is one direct contact (H-bond) between capreomycin and residue 1491, while viomycin 222 
forms no H-bonds with base pair 1409-1491. The strong effect of single C1409 or G1491 223 
alterations on tuberactinomycin activity most likely reflects the fact that the base pair forms 224 
an important binding surface for the macrocycle ring (Fig. 1 D-E) and mutations that break 225 
the base pair would induce structural rearrangements that affect drug-ribosome interaction. 226 
Restoration of canonical 1409-1491 Watson-Crick base pairing, e.g. 1409G-1491C, recovers 227 
the structure of h44 and in part relieves from the high-level resistance phenotype associated 228 
with single C1409 or G1491 alterations.  229 
The functional relevance of rRNA residues in codon-anticodon interaction and stabilization is 230 
reflected in the conservation of the small subunit’s decoding A site throughout evolution. 231 
However, critical variations have evolved between different phylogenetic domains, most 232 
prominent in h44 of the 16S rRNA. The binding site for tuberactinomycins in part overlaps 233 
that for aminoglycosides in h44 of the small ribosomal subunit. Both classes of antibiotics 234 
affect translocation of the tRNA on the ribosome, either by stabilizing the tRNA in the pre-235 
translocation state or by interfering with the conformational changes of the ribosome / tRNA 236 
required for translocation (24, 26). Compared to aminoglycosides the tuberactinomycin 237 
antibiotics induce little, if any misreading on bacterial ribosomes (19, see Fig. 3). 238 
Nevertheless, it was observed in the early 80’s that tuberactinomycin antibiotics may have the 239 
potential to provoke misreading on bacterial ribosomes, when using an in-vitro artificial 240 
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system composed of synthetic homopolynucleotides and non-cognate (rather than near-241 
cognate) tRNA as the sole species of aminoacylated tRNA. However, when the system was 242 
complemented with additional aminoacylated tRNAs a strong inhibition of translocation was 243 
the prevalent effect with concurrent loss of misreading (19). Both tuberactinomycins and 244 
aminoglycosides share irreversible hearing loss as a main unwanted effect (7). Similar to 245 
aminoglycosides, we suggest that the unwanted side effects of tuberactinomycin reflect 246 
limitations in compound selectivity, despite the observation that the tuberactinomycins show a 247 
several hundred-fold higher activity on bacterial compared to eukaryotic ribosomes (see Table 248 
2). In support of a common mechanism in aminoglycoside and tuberactinomycin ototoxicity 249 
we find that tuberactinomycins demonstrate key features involved in aminoglycoside 250 
ototoxicity: misreading induction in mitohybrid ribosomes and increased susceptibility of 251 
mutant mitohybrids with the A1555G and C1494U deafness alleles to drug action. However, 252 
the structural determinants of selectivity, i.e. the ability to differentiate between prokaryotic 253 
and eukaryotic ribosomes, are notably different. While for the clinically used 6’NH2 4,6-254 
aminoglycosides selectivity to a large extent rests upon 16S rRNA residue 1408 (14, 16), 255 
selectivity of tuberactinomycin antibiotics mainly involves 16S rRNA residue 1491. We 256 
suggest that the structures available together with the determinants of selectivity identified 257 
will enable the creation of new compounds by targeted drug design. The adjacent location of 258 
these two different classes of antibiotics should provide a means to combine their selectivity 259 
in an additive fashion without decreasing their potency as antibacterial agent, e.g. by 260 
chemically linking modified portions of tuberactinomycins and ring I of the 6’NH2 4,6-261 
aminoglycosides. These compounds will be particularly valuable for treatment of 262 
tuberculosis, as chemotherapy of tuberculosis requires several months of drug treatment, 263 
putting the patients at high risk for ototoxicity.  264 
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Figure Legends 373 
Figure 1. Binding site of tuberactinomycins viomycin and capreomycin. (A) Overview of the 374 
binding site of the tuberactinomycins (red) at the interface between the small (30S, yellow) 375 
and large (50S, blue) ribosomal subunits (37). A-(cyan) and P-tRNA (green) and h44 (orange) 376 
are coloured for reference. (B-C) enlargement of (A) to show binding site of (B) viomycin 377 
and (C) capreomycin to h44 (orange) of the 30S and H69 (blue) of the 50S, with the mRNA 378 
and A-tRNA coloured green and cyan, respectively. (D-E) Interaction of the 379 
tuberactinomycins within the ribosomal binding site. (D) Capreomycin (green) and (E) 380 
viomycin (cyan) form hydrogen bond interactions (magenta) with h44 of the 16S rRNA 381 
(orange) and H69 of the 23S rRNA (blue) (37). Intramolecular hydrogen bonds between 382 
rRNA nucleotides are coloured yellow. (F) Secondary-structure of decoding-site rRNA 383 
sequences in the small ribosomal subunit. Nucleotides depicted in green represent residues 384 
that were exchanged to residues shown in red. rRNA nucleotides are numbered according to 385 
the bacterial nomenclature, i.e., to homologous E. coli 16S rRNA positions.  386 
 387 
Figure 2. Top: Compensatory mutations in decoding-site of bacterial small ribosomal subunit 388 
rRNA. Nucleotides depicted in green represent residues that were exchanged to residues 389 
shown in red. Bottom: Secondary-structure comparison of decoding-site rRNA sequences in 390 
the small ribosomal subunit. (A) Decoding region of 16S rRNA helix 44 in wild-type 391 
ribosomes of M. smegmatis; rRNA nucleotides are numbered according to the bacterial 392 
nomenclature, i.e., to homologous E. coli 16S rRNA positions. (B) Homologous 18S rRNA 393 
sequence in human ribosomes; rRNA residues are numbered according to the human 394 
cytoplasmic ribosome nomenclature. (C) Homologous 12S rRNA sequence in human 395 
mitochondrial ribosomes; rRNA residues are numbered according to the mitochondrial 396 
nomenclature. (D–H) Decoding site rRNA of human–bacterial hybrid ribosomes. The 397 
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transplanted helix is boxed, and nucleotide positions depicted in blue represent residues that 398 
are specific for human rRNA. Mutations that are associated with hypersusceptibility to 399 
aminoglycoside antibiotics, mtDNA position 1555A → G (G), and 1494C → U (H) are 400 
highlighted in red.  401 
 402 
Figure 3. Effect of capreomycin and viomycin on misreading during translation elongation. 403 
Drug-induced misreading was quantified using the Arg245 (CGC) near-cognate mutant of 404 
firefly luciferase – closed circle: capreomycin, closed square: viomycin. The Arg245 (AGA) 405 
non-cognate mutant of firefly luciferase was used as misreading control – open circle: 406 
capreomycin, open square: viomycin. Bacterial ribosomes, mitohybrid ribosomes, mutant 407 
1555G mitohybrid ribosomes, mutant C1494U mitohybrid ribosomes are indicated. 408 
Misreading was calculated by comparing mutant firefly/renilla luciferase activity to wild-type 409 
His245 (CAC) firefly/renilla luciferase activity. The IC50 inhibitory values (drug 410 
concentrations which inhibit protein synthesis to 50%) are indicated; for comparison see 411 
Table 2. 412 
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Table 1 Activity of tuberactinomycins against mutant bacterial cells. 413 
 414 
MIC (µg/ml) 
rRNA Viomycin Capreomycin 
   
wt 4-8 4-8 
A1408G 4-8 32-64 
C1409U 16 64-128 
C1409G 512-1024 ≥1024 
G1491A 128-256 512 
G1491C 256-512 1024 
G1491U 256-512 ≥1024 
C1409U-G1491A 16-32 64 
C1409G-G1491C 16-32 64-128 
C1409A-G1491U 128 256-512 
 415 
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IC50 (µM) a 
Ribosomes Viomycin Capreomycin 
   
M. smegmatis bacterial ribosomes 0.03 ± 0.0057 0.03 ± 0.017 
Rabbit reticulocyte ribosomes 80 ± 12.6 50 ± 4.5 
Cytohybrid ribosomes (cyt 14) 16 ± 0.6 52 ± 11.7 
1408G / 1491A ribosomes (cyt 2) 53 ± 4.0 110 ± 5.8 
Mitohybrid ribosomes (mit 13) 45 ± 5.8 75 ± 10.4 
A1555G mutant mitohybrid ribosomes 11 ± 2.1 13 ± 1.1 
C1494U mutant mitohybrid ribosomes 12 ± 1.7 23 ± 4.0 
 419 
a
 Drug concentrations required to inhibit synthesis of active luciferase to 50 percent (IC50) 420 
 421 
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